Westhoff G, Listing J, Zink A
Deutsches Rheuma-Forschungszentrum Berlin, Forschungsbereich Epidemiologie, Schumannstrasse 21/22, 10117 Berlin, Germany.
Z Rheumatol. 2004 Oct;63(5):414-24. doi: 10.1007/s00393-004-0650-z.
We examined out-of-pocket medical expenditures (OoP) of 869 patients with recent onset rheumatoid arthritis (ACR criteria, disease duration <2 years) using data from a prospective observational cohort. Out-of-pocket costs were retrospectively assessed for a period of 6 months by a list of 14 cost domains. Of the patients, 82% had costs due to copayments for prescribed drugs and 56% for over-the-counter drugs. Within six months each patient spent an average of 47 (+/- 67) Euro as co-payment and 45 (+/- 96) Euro for over-the-counter drugs. A comparable sum was spent for complementary and alternative medicine (47+/-250 Euro), which was used by 14% of the patients. The mean total OoP expenditure caused by RA was 628 Euro p.a. (median 306, IQ 66-334 Euro). The median costs accounted for approximately 2% of the average disposable yearly income in Germany. Out-of-pocket spending increased with functional limitations, poor health condition and pain as well as with level of education. A multivariate logistical regression analysis showed that patients with these characteristics spent about twice as much as patients with mild disease or low educational level. The odds ratios for having more than 306 Euro OoP-costs p.a. were OR=2.6 (CI 1.7-4) for patients with severe vs. moderate functional disability (HAQ> or =1.5 vs <1.5), OR=2.4 (CI 1.4-4.4) for patients in poor vs. good health condition (NRS 7-10 vs 0-3), and OR=2.1 for patients with severe vs. mild pain (CI 1.4-3.3). The level of OoP spending also varied by employment status (OR=0.28; CI 0.1-0.6 for jobless vs employed patients). Despite almost universal insurance coverage in Germany, patients with rheumatoid arthritis were exposed to substantial OoP expenditures. As policymakers discuss cost sharing and design of benefit packages to contain health spending, it is important to consider the expenditures that persons with chronic conditions like rheumatoid arthritis already have.
我们利用一项前瞻性观察队列研究的数据,对869例近期发病的类风湿性关节炎患者(符合美国风湿病学会(ACR)标准,病程<2年)的自付医疗费用进行了研究。通过14个费用领域的清单对6个月期间的自付费用进行了回顾性评估。在这些患者中,82%的患者有处方药共付费用,56%的患者有非处方药共付费用。在6个月内,每位患者平均共付47(±67)欧元用于处方药,45(±96)欧元用于非处方药。用于补充和替代医学的费用与之相当(47±250欧元),14%的患者使用了补充和替代医学。类风湿性关节炎导致的平均年自付总费用为628欧元(中位数306欧元,四分位间距66 - 334欧元)。中位数费用约占德国平均年可支配收入的2%。自付费用随着功能受限、健康状况差、疼痛以及教育水平的提高而增加。多因素逻辑回归分析显示,具有这些特征的患者花费约为病情较轻或教育水平较低患者的两倍。每年自付费用超过306欧元的比值比,重度与中度功能残疾患者(健康评估问卷(HAQ)≥1.5 vs <1.5)为OR = 2.6(95%置信区间1.7 - 4),健康状况差与良好患者(数字评定量表(NRS)7 - 10 vs 0 - 3)为OR = 2.4(95%置信区间1.4 - 4.4),重度与轻度疼痛患者为OR = 2.1(95%置信区间1.4 - 3.3)。自付费用水平也因就业状况而异(失业患者与就业患者相比,OR = 0.28;95%置信区间0.1 - 0.6)。尽管德国几乎全民享有医保,但类风湿性关节炎患者仍面临大量自付费用。由于政策制定者在讨论成本分担和福利套餐设计以控制医疗支出时,考虑类风湿性关节炎等慢性病患者已有的支出很重要。